Luitpold Pharmaceuticals buys US injectable pharmaceuticals firm PharmaForce
Luitpold Pharmaceuticals, a US-based division of Japanese drugmaker Daiichi-Sankyo, has acquired PharmaForce, a specialist manufacturer of injectable pharmaceuticals to expand its product portfolio and increase its manufacturing capacity.
Luitpold Pharmaceuticals, a US-based division of Japanese drugmaker Daiichi-Sankyo, has acquired PharmaForce, a specialist manufacturer of injectable pharmaceuticals to expand its product portfolio and increase its manufacturing capacity.
The PharmaForce product line will be marketed by Luitpold's subsidiary, American Regent.
PharmaForce, founded in 1999, produces difficult-to-manufacture sterile products and generic injectable products. Headquartered in Columbus, Ohio, the company has three facilities, including a 3,700m2 cGMP compliant sterile manufacturing facility, a 1,858m2 r&d facility, and a 1,858m2 API manufacturing plant.
Mary Jane Helenek, president and ceo of Luitpold, said: "This acquisition provides an immediate expansion of our r&d pipeline, increased manufacturing capacity and establishes a base from which to move forward with different injectable dosage forms to take advantage of the fast-growing generic injectable market."
Luitpold Pharmaceuticals, headquartered in Shirley, NY, manufactures and distributes more than 65 pharmaceutical products, including Venofer (iron sucrose injection, USP), a leading IV iron therapy in the US, through its human health subsidiary, American Regent.
Luitpold also markets dental bone regeneration products and veterinary drugs through its Osteohealth and Animal Health divisions.